Exclusive rights in gastric cancer genomics

Gut

Volumn 61, Issue 5, 2012, Pages 638-640

  Petty, Russell D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

CANCER CLASSIFICATION; CANCER GENETICS; CANCER GROWTH; CLINICAL DECISION MAKING; COLORECTAL CANCER; COPY NUMBER VARIATION; DRUG EFFICACY; EGFR GENE; FGFR2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MET GENE; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NOTE; ONCOGENE K RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TRANSLATIONAL RESEARCH;

GENE AMPLIFICATION; GENE DELETION; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS;

EID: 84859570062     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302334     Document Type: Note

References (10)

1. Soria JC, Blay JY, Spano JP, et al. Added value of molecular targeted agents in oncology. Ann Oncol 2011;22:1703-16.
2. Weinstein IB, Joel A. Oncogene addiction. Cancer Res 2008;68:3077-80.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
4. Deng N, Goh LK, Wang H, et al. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Systematic Patterns of Molecular Exclusivity and Co-Occurrence among Distinct Therapeutic Targets. Gut 2012;61:673-84.
5. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-10.
6. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006;103:2316-21.
7. Kunii K, Davis L, Gorenstein J, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340-8. (Pubitemid 351521808)
8. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
9. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
10. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 2011;3:1787-808.